- Home
- VTVT vs FGEN Comparison
VTVT vs FGEN Comparison
Compare VTVT & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTVT
- FGEN
- Stock Information
- Founded
- VTVT 2015
- FGEN 1993
- Country
- VTVT United States
- FGEN United States
- Employees
- VTVT N/A
- FGEN N/A
- Industry
- VTVT Biotechnology: Pharmaceutical Preparations
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- VTVT Health Care
- FGEN Health Care
- Exchange
- VTVT Nasdaq
- FGEN Nasdaq
- Market Cap
- VTVT 54.4M
- FGEN 45.1M
- IPO Year
- VTVT 2015
- FGEN 2014
- Fundamental
- Price
- VTVT $20.90
- FGEN $10.74
- Analyst Decision
- VTVT Strong Buy
- FGEN Strong Buy
- Analyst Count
- VTVT 2
- FGEN 2
- Target Price
- VTVT $35.50
- FGEN $146.50
- AVG Volume (30 Days)
- VTVT 4.0K
- FGEN 26.5K
- Earning Date
- VTVT 11-11-2025
- FGEN 11-11-2025
- Dividend Yield
- VTVT N/A
- FGEN N/A
- EPS Growth
- VTVT N/A
- FGEN N/A
- EPS
- VTVT N/A
- FGEN N/A
- Revenue
- VTVT $17,000.00
- FGEN $7,346,000.00
- Revenue This Year
- VTVT N/A
- FGEN N/A
- Revenue Next Year
- VTVT N/A
- FGEN N/A
- P/E Ratio
- VTVT N/A
- FGEN N/A
- Revenue Growth
- VTVT N/A
- FGEN N/A
- 52 Week Low
- VTVT $12.62
- FGEN $4.50
- 52 Week High
- VTVT $26.99
- FGEN $21.94
- Technical
- Relative Strength Index (RSI)
- VTVT 48.99
- FGEN 45.30
- Support Level
- VTVT $19.83
- FGEN $10.37
- Resistance Level
- VTVT $21.20
- FGEN $11.65
- Average True Range (ATR)
- VTVT 0.89
- FGEN 0.62
- MACD
- VTVT -0.39
- FGEN -0.06
- Stochastic Oscillator
- VTVT 23.61
- FGEN 33.09
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin, being investigated for the treatment of type 1 diabetes (T1D). Its product pipeline includes TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.